Q4 2023 13F Holders as of 31 Dec 2023
-
Type / Class
-
Equity / Common Stock, par value $0.0001 per share
-
Shares outstanding
-
1,079,784,035
-
Number of holders
-
141
-
Total 13F shares, excl. options
-
57,525,605
-
Shares change
-
+7,650,404
-
Total reported value, excl. options
-
$288,814,721
-
Value change
-
+$55,491,609
-
Put/Call ratio
-
137%
-
Number of buys
-
82
-
Number of sells
-
-40
-
Price
-
$5.02
Significant Holders of ImmunityBio, Inc. - Common Stock, par value $0.0001 per share (IBRX) as of Q4 2023
166 filings reported holding IBRX - ImmunityBio, Inc. - Common Stock, par value $0.0001 per share as of Q4 2023.
ImmunityBio, Inc. - Common Stock, par value $0.0001 per share (IBRX) has 141 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 57,525,605 shares
of 1,079,784,035 outstanding shares and own 5.3% of the company stock.
Largest 10 shareholders include VANGUARD GROUP INC (13,328,525 shares), BlackRock Inc. (10,710,179 shares), STATE STREET CORP (9,470,909 shares), GEODE CAPITAL MANAGEMENT, LLC (3,379,464 shares), CREDIT SUISSE AG/ (1,529,908 shares), JPMORGAN CHASE & CO (1,422,212 shares), NORTHERN TRUST CORP (1,357,059 shares), GOLDMAN SACHS GROUP INC (1,278,638 shares), CHARLES SCHWAB INVESTMENT MANAGEMENT INC (1,142,925 shares), and BANK OF AMERICA CORP /DE/ (891,815 shares).
This table shows the top 141 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.